RxDoctor Payments Data

Alexandra Johnston, DO

Internal Medicine · Pittsburgh, PANPI 1033504253

Payments from drug & device makers

$648in general payments, 2019–2025

Across 19 payments — averaging $34.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$117
  • Johnson & Johnson$116
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$97
  • Merck$86
  • Daiichi Sankyo Inc.$86
  • Novo Nordisk$84
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$648 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$32,019
Medicare patients
78
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin77$76,497
OzempicSemaglutide31$35,101
TrulicityDulaglutide31$30,157
MounjaroTirzepatide13$13,516
LinzessLinaclotide21$10,911
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,061
Amlodipine-ValsartanAmlodipine Besylate/Valsartan18$2,346
Atorvastatin Calcium150$1,467
Valsartan37$1,378
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,337
Albuterol Sulfate HfaAlbuterol Sulfate25$940
Rosuvastatin Calcium72$705
Spironolactone-HctzSpironolact/Hydrochlorothiazid13$670
Amlodipine Besylate153$611
Ezetimibe18$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$84$35,10131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →